DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, December 2016.
Tumour necrosis factor (TNF) is a cytokine associated with inflammatory disorders of the skin, joints, and gastrointestinal tract.
The most active tumour necrosis factor inhibitors (anti-TNF drugs) are monoclonal antibodies targeted against TNF-alpha (TNFα). Anti-TNFα drugs control inflammation in inflammatory skin diseases, arthritis, and bowel disease. They were among the first biologic agents on the market.
Anti-TNFα monoclonal antibodies include:
Other drugs with activity against TNF include:
Natural compounds acting against TNF include:
The anti-TNF monoclonal antibodies are used mainly in the treatment of severe chronic plaque psoriasis.
They are also used for other severe inflammatory skin diseases when conventional therapies have failed. Examples include:
Skin conditions treated with tumour necrosis factor inhibitors
Anti-TNF biologics are given by injection. They can sometimes cause injection site reactions or infusion reactions.
They should be avoided in patients with severe heart failure.
The main risk of anti-TNF therapy is reduced immunity to bacterial, fungal, viral, and parasitic infections, including:
Anti-TNF medicines can lose their effect over time, possibly because of the induction of antibodies against them. Paradoxically, anti-TNF drugs can sometimes result in dermatological side effects, such as:
Dermatological side effects of tumour necrosis factor inhibitors
See the DermNet NZ bookstore.
The New Zealand approved datasheet is the official source of information for this prescription medicine, including approved uses and risk information. Check the New Zealand datasheet on the Medsafe website.
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.